112 related articles for article (PubMed ID: 8782990)
1. c-erb B-2 and p53 expression in breast cancer fine needle aspirates.
Tiniakos DG; Robinson KB; Greenwood H; Cullen P; Cook AI; Horne CH; Angus B
Cytopathology; 1996 Jun; 7(3):178-86. PubMed ID: 8782990
[TBL] [Abstract][Full Text] [Related]
2. Image analysis (DNA ploidy) and expression of c-erb B-2 and p53 in imprint smears of breast cancer.
Malle D; Patakiouta F; Bousoulegas A; Karakitsos P; Destouni C
Eur J Gynaecol Oncol; 2003; 24(6):531-4. PubMed ID: 14658596
[TBL] [Abstract][Full Text] [Related]
3. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors.
Corkill ME; Katz R
Diagn Cytopathol; 1994; 11(3):250-4. PubMed ID: 7867467
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
[TBL] [Abstract][Full Text] [Related]
7. Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study.
Tweedie E; Tonkin K; Kerkvliet N; Doig GS; Sparrow RK; O'Malley FP
Clin Invest Med; 1997 Oct; 20(5):300-7. PubMed ID: 9336655
[TBL] [Abstract][Full Text] [Related]
8. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
Rozan S; Vincent-Salomon A; Zafrani B; Validire P; De Cremoux P; Bernoux A; Nieruchalski M; Fourquet A; Clough K; Dieras V; Pouillart P; Sastre-Garau X
Int J Cancer; 1998 Feb; 79(1):27-33. PubMed ID: 9495354
[TBL] [Abstract][Full Text] [Related]
9. The role of ThinPrep cytology in the investigation of ki-67 index, p53 and HER-2 detection in fine-needle aspirates of breast tumors.
Konofaos P; Kontzoglou K; Parakeva P; Kittas C; Margari N; Giaxnaki E; Pouliakis M; Kouraklis G; Karakitsos P
J BUON; 2013; 18(2):352-8. PubMed ID: 23818345
[TBL] [Abstract][Full Text] [Related]
10. Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method.
Alexiev BA
Diagn Cytopathol; 1996 Nov; 15(4):277-81. PubMed ID: 8982580
[TBL] [Abstract][Full Text] [Related]
11. p53 protein expression in fine-needle aspirates of breast cancer: an immunocytochemical assay for identifying high-grade ductal carcinomas.
Colecchia M; Frigo B; Zucchi A; Leopardi O
Diagn Cytopathol; 1995 Aug; 13(2):128-32; discussion 132-3. PubMed ID: 8542791
[TBL] [Abstract][Full Text] [Related]
12. Primary breast carcinoma: immunocytochemical and immunohistochemical evaluation of biological parameters.
Sianesi M; Bozzetti C; Del Rio P; Nizzoli R; Cascinu S
Chir Ital; 2000; 52(6):643-5. PubMed ID: 11199998
[TBL] [Abstract][Full Text] [Related]
13. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma.
Midulla C; Giovagnoli MR; Valli C; Vecchione A
Anal Quant Cytol Histol; 1995 Jun; 17(3):157-62. PubMed ID: 7546049
[TBL] [Abstract][Full Text] [Related]
14. Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.
Fernando IN; Powles TJ; Dowsett M; Ashley S; McRobert L; Titley J; Ormerod MG; Sacks N; Nicolson MC; Nash A
Virchows Arch; 1995; 426(2):155-61. PubMed ID: 7757286
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 1 aneusomy with 1p36 under-representation is related to histologic grade, DNA aneuploidy, high c-erb B-2 and loss of bcl-2 expression in ductal breast carcinoma.
Farabegoli F; Ceccarelli C; Santini D; Trerè D; Baldini N; Taffurelli M; Derenzini M
Int J Cancer; 1996 Oct; 69(5):381-5. PubMed ID: 8900371
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
[TBL] [Abstract][Full Text] [Related]
18. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases.
Briffod M; Hacène K; Le Doussal V
Mod Pathol; 2000 Aug; 13(8):841-50. PubMed ID: 10955449
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
